Unexplained weight loss (UWL), defined as a decrease of 5% or more in body weight over a period of 6 to 12 months without a clear cause, poses a significant diagnostic challenge in clinical practice. This article aims to provide a comprehensive approach to the evaluation and management of UWL.
UWL can be the result of a variety of underlying conditions, including gastrointestinal diseases, malignancies, endocrine disorders, mental health conditions, and infectious diseases. It can also be a side effect of certain medications. A thorough history and physical examination are crucial in identifying potential causes.
A stepwise approach is recommended for the evaluation of UWL. Initial investigations should include a comprehensive metabolic panel, complete blood count, thyroid function tests, and urinalysis. If these tests are inconclusive, further investigations such as imaging studies, endoscopy, or biopsy may be warranted based on the patient's symptoms and risk factors.
Management of UWL primarily involves treating the underlying condition. In cases where no clear cause is identified, a symptom-focused approach may be beneficial. This may include nutritional support, medication review, and psychological interventions. Regular follow-up is essential to monitor the patient's progress and reassess the diagnosis if necessary.
While UWL can be a perplexing diagnostic dilemma, a systematic and comprehensive approach can aid in the identification and management of the underlying cause. It is crucial for healthcare professionals to consider a broad differential diagnosis and to utilize appropriate diagnostic tools in a stepwise manner. Regular patient follow-up and reassessment are key in ensuring effective management and positive patient outcomes.
1.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Radiation therapy can promote amphiregulin, which increases growth of metastases
5.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
Essential Strategies in Hematology for Healthcare Excellence
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
5.
Lymphomatoid Papulosis: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation